# CheckMate 743 (NCT02899299)

> Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab
- Indication: first-line unresectable malignant pleural mesothelioma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02899299
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Mesothelioma
- Interventions: Nivolumab; Ipilimumab; Pemetrexed; Cisplatin; Carboplatin
- Enrollment: 605
- Primary outcome: Overall Survival (OS)

## Indexed commentary on CheckMate 743 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 86 posts on X
- 20 podcast episodes
- 6 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=checkmate-743-nct02899299

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02899299", "email": "<work email>"}; the inbox owner confirms by the emailed link.